[Treatment of erectile dysfunction with vacuum pumps].
A Vacuum constrictor device (VCD) was tested in 90 patients with organic erectile failure, some of whom had positive and some, negative responses to intracavernous self-injection of vasoactive drugs. Acceptance of the VCD overall was 37%. Among the 49 patients who did not respond to intracavernous injection of vasoactive drugs, acceptance was 45%, clearly higher than among the 41 responders to the injections, only 27% of whom accepted the VCD. Isolated subcutaneous hematomas were the only noteworthy complications observed with long-term therapy (up to 3 years). In cases of so-called venous leakage, the degree of venous outflow disturbance limited the use of the VCD, even in combination with self-injection therapy. The VCD is a successful alternative therapeutic option for the treatment of organic erectile failure, with a lower primary acceptance than corpus cavernosum self-injection therapy.
Derouet
H
H
Urologische Universitätsklinik und Poliklinik, Homburg/Saar.
Zehl
U
U
D000328:Adult; D000368:Aged; D000527:Alprostadil / Q000008:administration & dosage; D003131:Combined Modality Therapy; D004359:Drug Therapy, Combination; D007172:Erectile Dysfunction / Q000209:etiology / Q000628:therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010208:Papaverine / Q000008:administration & dosage; D010342:Patient Acceptance of Health Care; D010413:Penis / Q000098:blood supply; D010646:Phentolamine / Q000008:administration & dosage; D013396:Suction / Q000295:instrumentation*; D014618:Vacuum; D014689:Venous Insufficiency / Q000150:complications / Q000628:therapy*
D010208:Papaverine; D000527:Alprostadil; D010646:Phentolamine